Back to Results

Solventum Corp (SOLV)

Solventum Corp is a healthcare company listed on the NYSE under the ticker SOLV. The company develops, manufactures, and commercializes a range of solutions designed to address customer and patient needs in the United States and international markets. Its operations are organized into three segments: Medsurg, Dental Solutions, and Health Information Systems.

The Medsurg segment includes products and technologies used in wound care, skin care, sterilization assurance, temperature management, surgical supplies, medical tapes, stethoscopes, and related applications. Dental Solutions covers products for preventive care, restorative treatments, and orthodontic use, including brackets, aligners, cements, and bonding agents. Health Information Systems provides software and workflow tools such as physician documentation, coding automation, speech recognition, classification methods, and data visualization platforms. Solventum was incorporated in 2023 and is headquartered in Eagan, Minnesota.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-SOLV
$86.13
9.0% Upside
Fair
$83.38
5.5% Upside
Fair
Good
—
—
—
0.0%
August 5, 2026
9.6x
2.8x
1.7x
13.724 B
18.407 B
27.8%
84.9%
3.1
—
-14.2%
Send a message
Valuation • Fair Value

Solventum Corp (NYSE-SOLV) Fair Value by Valuation Model

Compare the primary fair value estimate for Solventum Corp (NYSE-SOLV) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$86.13

Estimated upside of 9.0% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$94.38

Discounted cash flow valuation reference.

Ben Graham Formula Value

$91.75

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$87.57

Earnings power value estimate.

Comps Fair Value

$77.64

Comparable-company valuation reference.

Analyst Price Target

$83.38

Analysts imply upside of 5.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Solventum Corp (NYSE-SOLV) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Solventum Corp (NYSE-SOLV)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

8.262 B

Current operating scale indicator.

Revenue Forecast

8.21 B

Forward revenue estimate.

EBITDA

1.124 B

Current operating profitability reference.

EBITDA Forecast

1.897 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Solventum Corp (NYSE-SOLV) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Solventum Corp (NYSE-SOLV)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-1.94

Intermediate zone that deserves monitoring.

Altman Z-Score

3.1

Relatively strong balance-sheet zone.

FCF / Net Income

-14.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Solventum Corp (NYSE-SOLV). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Solventum Corp (NYSE-SOLV)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 5, 2026

Days to Earnings

15

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Solventum Corp (NYSE-SOLV), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Solventum Corp (NYSE-SOLV) Stock Forecast & Technical Outlook

Review Solventum Corp (NYSE-SOLV) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Solventum Corp (NYSE-SOLV) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Solventum Corp (NYSE-SOLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Solventum Corp (NYSE-SOLV) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Solventum Corp (NYSE-SOLV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Solventum Corp (NYSE-SOLV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Solventum Corp (NYSE-SOLV)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Solventum Corp (NYSE-SOLV) has a Hold consensus, with 6 buy, 6 hold and 1 sell recommendations in the current data set.

Buy 6
Hold 6
Sell 1
FAQ • Fast Investor Answers

Solventum Corp (NYSE-SOLV) Stock FAQ

Quick answers about Solventum Corp (NYSE-SOLV) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$86.13
Estimated upside 9.0%
Valuation Rating
Undervalued
Estimated upside of 9.0%
Analyst Target
$83.38
Implied upside 5.5%
Financial Health
Good
Current financial-health read

The current fair value estimate for Solventum Corp (NYSE-SOLV) is $86.13. This implies an estimated upside of 9.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 9.0% versus the current market price.

The available analyst price target for Solventum Corp (NYSE-SOLV) is $83.38. The analyst target implies estimated upside of 5.5%.

The current financial health read for Solventum Corp (NYSE-SOLV) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Solventum Corp (NYSE-SOLV) is August 5, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Solventum Corp (NYSE-SOLV) is 9.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Solventum Corp is 13.724 B.

The current enterprise value listed for Solventum Corp is 18.407 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Solventum Corp is NYSE-SOLV, and the stock is listed on NYSE.

Solventum Corp (NYSE-SOLV) is listed on NYSE.

The current debt-to-total-capital ratio listed for Solventum Corp is 27.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Solventum Corp is 84.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)